Skip to main content

Anti-TNF antibody therapy induces IL-17 suppressing regulatory T cells in patients with rheumatoid arthritis

Biologic therapies not only offer the prospect of improved patient outcomes in a variety of autoimmune diseases, but also the opportunity to explore the specific target's role in the underlying mechanisms of disease. Over recent years we have studied the role of regulatory T cells (Treg) in patients with rheumatoid arthritis before and after anti-TNF therapy. We have shown that Treg from patients with rheumatoid arthritis have defective suppressor function. This Treg defect is linked with abnormalities in the expression and function of CTLA-4. Anti-TNF antibody therapy did not reverse CTLA-4 dysfunction but instead induced the differentiation of a distinct and potent Treg population. These induced Treg were able to inhibit IL-17 production, in contrast to Treg from healthy individuals, patients with active RA or RA patients treated with etanercept, a modified TNF receptor. These results may provide mechanistic insight into the therapeutic benefit of switching between different anti-TNF agents and the differing incidence of tuberculosis between adalimumab and etanercept.

Author information

Affiliations

Authors

Corresponding author

Correspondence to Jenny McGovern.

Rights and permissions

Reprints and Permissions

About this article

Cite this article

McGovern, J., Notley, C.A., Nguyen, D. et al. Anti-TNF antibody therapy induces IL-17 suppressing regulatory T cells in patients with rheumatoid arthritis. Arthritis Res Ther 14, O42 (2012). https://doi.org/10.1186/ar3597

Download citation

Keywords

  • Rheumatoid Arthritis
  • Tuberculosis
  • Etanercept
  • Adalimumab
  • Specific Target